In a significant development related to ongoing patent litigation with 10x Genomics, Bruker Corporation has successfully posted a bond authorized by the Munich Higher Regional Court. This move has led to the immediate suspension of the injunction that was adversely affecting the sales of NanoString’s CosMx Spatial Molecular Imager (SMI) products in Germany. As a result, all CosMx products are now once again available for purchase.
The injunction, which had impacted the sales of the CosMx SMI products, is related to the ongoing patent dispute with 10x Genomics during the appeal process in Germany. Bruker Corporation’s ability to post the bond has led to the temporary suspension of the injunction, providing relief for NanoString’s business operations in Germany.
In a separate announcement, Bruker Corporation unveiled its latest innovation, the neofleX Imaging Profiler, a high-performance MALDI-TOF/TOF system for mass spectrometry-based tissue imaging. This novel system offers convenient OME-TIFF file output through the SCiLS Scope software, providing users with enhanced capabilities for spatial biology mass spectrometry imaging (MSI) applications. The neofleX MALDI-TOF/TOF MSI system is designed to fit on a bench-top, making it easily accessible for researchers.
Additionally, Bruker Corporation has scheduled an Investor Webinar on May 17, 2024, from 10 am to about 12 noon Eastern Daylight Time (EDT). During this webinar, CEO Frank H. Laukien, CFO Gerald Herman, and other key executives will share insights into the recent acquisitions of Chemspeed, ELITech, and the NanoString business. Bruker Corporation also plans to provide an update on its medium-term financial outlook during the event.
In conclusion, the suspension of the injunction impacting NanoString’s CosMx SMI products in Germany is a positive development for Bruker Corporation. With the resumption of sales, NanoString will regain market traction, enabling the company to continue serving its customers and advancing its spatial molecular imaging capabilities. The launch of the neofleX Imaging Profiler further reaffirms Bruker’s commitment to innovative solutions in mass spectrometry-based tissue imaging. The upcoming Investor Webinar offers stakeholders the opportunity to gain deeper insights into the recent acquisitions and the company’s future financial outlook.
Comments